Spondyloarthropathies News

Patients with autoimmune diseases or long COVID who used a personalized digital care program alongside other non-pharmacologic strategies were more likely to achieve better health-related quality of life scores, according to data.

Cyltezo, the first interchangeable Humira biosimilar, officially entered the U.S. market on July 1, opening a floodgate that will see the release this month of half a dozen biosimilars for what has been the top selling drug in the country.

Patients with immune checkpoint inhibitor-associated inflammatory arthritis who receive a biologic DMARD demonstrate quicker arthritis control, but also experience faster cancer progression, vs. methotrexate, according to data.

Patients with anxiety or depression are less likely to exhibit healthy self-management for their rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis, according to data presented at EULAR 2023 Congress.

CHICAGO — In patients with inflammatory bowel disease, a “strong and consistent three-way interaction” was identified between HLA-B27, male sex and the development of sacroiliitis, according to data presented at Digestive Disease Week.

EULAR has launched RheumaFacts, a novel resource for local and national data regarding rheumatic and musculoskeletal diseases in Europe, according to a presenter at the EULAR 2023 Congress.

Managing comorbidities is critical to minimizing deaths in patients with rheumatic and musculoskeletal diseases, according to data presented at EULAR 2023 Congress.

Coherus BioSciences’ adalimumab biosimilar, Yusimry, will make its debut in the U.S. marketplace this summer at an 85% discount compared with the originator Humira, according to the manufacturer.

In patients with residual axial spondyloarthritis disease activity, many physicians avoid strict adherence to treat-to-target guidelines in favor of low disease activity, based on their own opinion, as a treatment goal, according to data.

Properly managing cardiovascular disease in patients with immune-mediated inflammatory diseases requires following guidelines and inter-specialty collaboration, according to a speaker at the Biologic Therapies Summit.